Business
Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence
Dr. Sharma and Mr. Olsheim bring more than 30 years of combined experience in the global pharmaceutical and biotechnology industry from their various roles
About this update from Outlook Therapeutics, Inc.
[{"type":"text","content":"Dr. Sharma and Mr. Olsheim bring more than 30 years of combined experience in the global pharmaceutical and biotechnology industry from their various roles launching and commercializing ophthalmic products\nISELIN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the appointments of Surendra Sharma, MD, as Senior Vice President, Medical Affairs, and Glen Olsheim as Executive Director, Commercial Excellence. “Outlook Therapeutics is very happy to welcome Surendra and Glen to our growing executive leadership team. Their respective backgrounds in directing the medical affairs of an ophthalmic portfolio and of driving the successful launch and commercialization of ophthalmic products will be tremendously valuable as we move towards the commercial launch of ONS-5010 ophthalmic bevacizumab, pending its approval by the U.S. FDA,” said Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics. Dr. Sharma has more than 15 years of experience in the pharmaceutical and biotechnology industries leading corporate alliances among R&D, commercial, marketing and business stakeholders. Most recently, he was Senior Medical Director, Cornea, Dry Eye and Retina, Global Medical Affairs at Santen Pharmaceuticals, Ltd. Over the course of his career at companies including Spark Therapeutics, Inc., Biogen Inc., Alcon Laboratories, Inc. and Regeneron Pharmaceuticals, Inc., he led global scientific communications strategies designed to align and meet the needs of key stakeholders in the North American and global markets. Dr. Sharma’s ability to create and maintain key relationships between the Company and key opinion leaders, the medical and scientific community, patients and advocacy groups, health authorities, and regulatory agencies will be instrumental for Outlook Therapeutics’ potential launch and commercialization of ONS-5010 ophthalmic bevacizumab. In his new role as SVP of Medical Affairs, Dr. Sharma will report to Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics. Dr. Sharma commented, “I am excited to join Outlook Therapeutics at this important inflection point in the Company’s development of ONS-5010,...